- Home
- / PAVmed
PAVmed
Stock Price
$1.1
2024-10-29
Market Capitalization
$10.5 M
2024-10-29
Revenue
$71 K
FY, 2025
PAVmed Summary
Company Summary
- Overview
- PAVmed is a company that provides medical technology. It operates through two segments: Lucid Diagnostics and Veris Health. Lucid Diagnostics focuses on diagnostic tests for detecting esophageal precancer and cancer. Veris Health provides personalized cancer care through remote patient monitoring using a digital health platform and connected health devices.
- Type
- Public
- Status
- Active
- Founded
- 2014
- HQ
- New York, NY, US | view all locations
- Website
- https://www.pavmed.com/
- Cybersecurity rating
Table of Contents
Key People
Michael Glennon, Director
Dennis McGrath, President and Chief Financial Officer
Brian Deguzman, Executive Vice President, Chief Technology & Compliance Officer
LocationsView all
2 locations detected
New York, NY HQ
United States
360 Madison Ave, Floor 25
New York, NY
United States
One Grand Central Place Suite 4600
PAVmed Financials
Summary Financials
- Revenue (FY, 2025)
- $71.0K
- Gross profit (FY, 2025)
- ($147.0K)
- Net income (FY, 2025)
- ($2.5M)
- Cash (FY, 2025)
- $1.5M
- EBIT (FY, 2025)
- ($21.8M)
- Enterprise value
- $33.5M